Publications by the researcher in collaboration with JOAQUÍN MARTÍNEZ LÓPEZ (76)

2023

  1. 17th International Conference on Malignant Lymphoma, Palazzo dei Congressi, Lugano, Switzerland, 13 - 17 June, 2023

    Hematological oncology

  2. Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia

    JCI Insight, Vol. 8, Núm. 2

  3. CNL and aCML should be considered as a single entity based on molecular profiles and outcomes

    Blood Advances, Vol. 7, Núm. 9, pp. 1672-1681

  4. Clinical Outcomes of Patients with Multiple Myeloma after Daratumumab Failure

    Life, Vol. 13, Núm. 9

  5. Correction: Large-scale real-life analysis of survival and usage of therapies in multiple myeloma (Journal of Hematology & Oncology, (2023), 16, 1, (76), 10.1186/s13045-023-01474-w)

    Journal of Hematology and Oncology

  6. Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients

    Frontiers in immunology

  7. Corrigendum: Personalized monitoring of circulating tumor DNA with a specific signature of trackable mutations after chimeric antigen receptor T-cell therapy in follicular lymphoma patients (Frontiers in Immunology, (2023), 14, (1188818), 10.3389/fimmu.2023.1188818)

    Frontiers in Immunology

  8. Large-scale real-life analysis of survival and usage of therapies in multiple myeloma

    Journal of Hematology and Oncology

  9. Multidisciplinary management in chronic myeloid leukemia improves cardiovascular risk measured by SCORE

    Frontiers in Pharmacology, Vol. 14

  10. Posttranslational splicing modifications as a key mechanism in cytarabine resistance in acute myeloid leukemia

    Leukemia, Vol. 37, Núm. 8, pp. 1649-1659

  11. Real-life disease monitoring in follicular lymphoma patients using liquid biopsy ultra-deep sequencing and PET/CT

    Leukemia, Vol. 37, Núm. 3, pp. 659-669

  12. Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia

    British Journal of Haematology